On August 2, 2023, the Linping District Biomedical Association was officially established, with EastPoint Innovation elected as the vice president, affirming its role as a trailblazer in Linping District's biomedicine high-quality development journey. The association's inception marks a significant step towards consolidating the prowess of biopharmaceutical enterprises, facilitating resource integration, fostering deeper industrial collaborations, and propelling the biopharmaceutical industry's high-quality evolution in the region.

Since its establishment in June 2021, EastPoint Innovation Center Co., Ltd., has been at the forefront of China's innovative medical device research and development, holding essential accreditations such as the Laboratory Animal Use License and Radiation Safety License. In the upcoming months, it will further bolster its credentials with qualifications like CNAS and CMA. Specializing in functional and safety evaluations of large animal experimental medical devices, biological assessments, material analysis, and clinical research consultancy, EastPoint Innovation serves as a comprehensive platform for medical technology innovation.

With a commitment to tailor-made solutions, EastPoint Innovation offers personalized integrated service models spanning from preclinical research to clinical trials and registration consultancy. By understanding each client's unique needs and the specifics of their medical device products, it aims to furnish essential preclinical research data, facilitate clinical trials, and streamline the registration process.

Looking ahead, EastPoint Innovation pledges to fulfill its duties as the vice president unit, working hand in hand with the Linping District Biomedical Association to spearhead technological breakthroughs, augment overall capabilities, foster collaboration, and steadfastly drive the biopharmaceutical sector's growth in Linping District.